Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system

References

• Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther. 2008;30(10):1747–1765.
   PubMed Web of Science ®Google Scholar
• Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51(18):5843–5855.
   PubMed Web of Science ®Google Scholar
• Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC. Long-term efficacy and safety of raltegravir in the management of HIV infection. Infect Drug Resist. 2014;7:73–84.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug Approval Package for Isentress (raltegravir). In: Administration UFaD, ed. Washington, DC: US Food and Drug Administration; 2008.
   Google Scholar
• US Food and Drug Administration. HIV/AIDS historical time line 2000 - 201. In: Administration UFaD, ed. Washington, DC: US Food and Drug Administration; 2014.
   Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013;13(7):587–596.
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Markowitz M, Ratanasuwan W, et al. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr. 2012;61(1):73–77.
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125–133.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77–85.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50(4):605–612.
   PubMed Web of Science ®Google Scholar
• Young B, Vanig T, DeJesus E, et al. 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naive HIV-1-infected patients: the SHIELD trial. HIV Clin Trials. 2011;12(4):228–233.
   PubMed Web of Science ®Google Scholar
• Adolescents PoAGfAa. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. In: Services DoHaH, ed. 2016:1–128.
   Google Scholar
• European AIDS Clinical Society. European AIDS clinical society guidelines version 8.2. In: Society EAC, ed. Vol 8.2: European AIDS Clinical Society; 2017:1–97.
   Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387–402.
   PubMed Web of Science ®Google Scholar
• Cole SR, Edwards JK, Hall HI, et al. Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including raltegravir or efavirenz among adults in the United States. Clin Infect Dis. 2017;64(11):1591–1596.
   PubMed Web of Science ®Google Scholar
• Hurt CB, Napravnik S, Moore RD, Eron JJ, Jr. Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C. Antivir Ther. 2014;19(4):415–422.
   PubMed Web of Science ®Google Scholar
• Surgers L, Lacombe K. Hepatoxicity of new antiretrovirals: a systematic review. Clin Res Hepatol Gastroenterol. 2013;37(2):126–133.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Ricci E, Molteni C, et al. Low frequency of skin reactions in a cohort of patients on raltegravir. J Antimicrob Chemother. 2012;67(7):1800–1802.
   PubMed Web of Science ®Google Scholar
• Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012;59(5):489–493.
   PubMed Web of Science ®Google Scholar
• Yao AH, Moore CL, Lim PL, et al. Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial. Antivir Ther. 2018;23(1):21–32.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Stentarelli C, Zona S, Santoro A. HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs. 2013;73(13):1431–1450.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Moser C, Currier J, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis. 2016;62(7):853–862.
   PubMed Web of Science ®Google Scholar
• Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22(7):841–848.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Chene G. Evolving epidemiology of malignancies in HIV. Curr Opin Oncol. 2008;20(5):534–540.
   PubMed Web of Science ®Google Scholar
• Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS. 2009;23(8):875–885.
   PubMed Web of Science ®Google Scholar
• Teppler H, Brown DD, Leavitt RY, et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011;9(1):40–53.
   PubMed Web of Science ®Google Scholar
• Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr. 2013;62(5):525–533.
   PubMed Web of Science ®Google Scholar
• Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 2015;45(3):289–294.
   PubMed Web of Science ®Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82(2):143–156.
   PubMed Web of Science ®Google Scholar
• Cozzi-Lepri A, Zangerle R, Machala L, et al. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med. 2018;19(2):102–117.
   PubMed Web of Science ®Google Scholar
• Bradford PT, Michal Freedman D, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010;146(3):265–272.
   PubMedGoogle Scholar
• Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis. 2017;65(4):636–643.
   PubMed Web of Science ®Google Scholar
• Asgari MM, Ray G, Quesenberry CP Jr, Katz KA, Silverberg MJ. Association of multiple primary skin cancers with human immunodeficiency virus infection, cd4 count, and viral load. JAMA Dermatol. 2017;153(9):892–896.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2551–2559.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Horberg MA, et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167(7):684–691.
   PubMed Web of Science ®Google Scholar
• Spire B, Nait-Ighil L, Pugliese P, et al. Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING. HIV Clin Trials. 2017;18(1):1–16.
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):1890–1892.
   PubMed Web of Science ®Google Scholar
• Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Curr Opin HIV AIDS. 2018;13(2):102–111.
   PubMed Web of Science ®Google Scholar
• Cahn P, Rolón MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20(1):21678.
   PubMed Web of Science ®Google Scholar